Skip to content

A randomised, double-blind, placebo-controlled study on the impact of doxycycline on aversive memory in healthy individuals

A randomised, double-blind, placebo-controlled study on the impact of doxycycline on aversive memory in healthy individuals - DoxAv

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00017037
Enrollment
560
Registered
2019-11-05
Start date
2019-10-29
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy subjects

Interventions

Group 1: Vibramycin® Tabs (Doxycyline), 200mg capsule, oral administration, single-dose. 6 experiments will examine whether aversive memories of healthy participants can be influenced by the antibiot

Sponsors

Department of Psychiatry, Psychotherapy, Psychosomatics, University of Zurich
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: - Informed Consent as documented by signature - Age 18 – 40 years

Exclusion criteria

Exclusion criteria: • Allergy to doxycycline or to any other ingredient in the named drugs • Use of any drugs in the 2 weeks prior to the study with the exception of contraceptive drugs and incidental use of NSARs or paracetamol • Women who are pregnant or breast feeding, • Intention to become pregnant during the course of the study, • Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration • Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.) • Any history of psychiatric, neurological, addiction, or systemic/rheumatic disease • Known or suspected non-compliance, drug or alcohol abuse • Inability to follow the procedures of the study, e.g. due to language problems • Participation in another study with investigational drug within 30 days preceding and during the present study, • Previous enrolment into the current study, • Members of the study team and their family members and dependants • Regular work in a medical profession • Life time history of being a victim of interpersonal violence or other potentially traumatic experience, or close relative of a person with such history

Design outcomes

Primary

MeasureTime frame
Primary endpoints are updated prompt to the start of a new experiment. Experiment 1 and 2: Fear-potentiated startle, measured via eyeblink EMG of the M. orbicularis oculi and quantified according to Khemka et al. (2017) Detailed analysis plan: https://osf.io/6kj5u/. Experiment 5: Quantity and distress of intrusion in an intrusion diary during one week following the trauma film

Secondary

MeasureTime frame
Experiment 1 und 2: SCR (skin conductance response), respiration amplitude, heart period measured with ECG (Electrocardiogram), pupil reaction, neuropsychological tests (e.g. VLM-T), questionnaires (STAI). Experiment 5: Questionnaires (e.g. STAI, BIS-BAS), SCR (skin conductance response), respiration amplitude, heart period measured with ECG (Electrocardiogram), neuropsychological tests (e.g. VLM-T).

Countries

Switzerland

Contacts

Public ContactJelena Wehrli

Department of Psychiatry, Psychotherapy, Psychosomatics, University of Zurich

jelena.wehrli@bli.uzh.ch+41 44 384 26 60

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026